8.22
+0.3998(+5.11%)
Currency In USD
| Previous Close | 7.82 |
| Open | 7.79 |
| Day High | 8.31 |
| Day Low | 7.71 |
| 52-Week High | 11.78 |
| 52-Week Low | 4.06 |
| Volume | 269,250 |
| Average Volume | 908,005 |
| Market Cap | 1.29B |
| PE | -6.13 |
| EPS | -1.34 |
| Moving Average 50 Days | 8.66 |
| Moving Average 200 Days | 8.07 |
| Change | 0.4 |
If you invested $1000 in Ocular Therapeutix, Inc. (OCUL) 10 years ago, it would be worth $269.94 as of February 05, 2025 at a share price of $8.22. Whereas If you bought $1000 worth of Ocular Therapeutix, Inc. (OCUL) shares 5 years ago, it would be worth $1,691.32 as of February 05, 2025 at a share price of $8.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting
GlobeNewswire Inc.
Feb 03, 2025 12:00 PM GMT
BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming presentations at the Angiogenesis, Exudation, a
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
GlobeNewswire Inc.
Jan 14, 2025 12:00 PM GMT
311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024 First wet AMD registrational trial, SOL-1, completed randomization in December 2024
Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation
GlobeNewswire Inc.
Jan 08, 2025 12:00 PM GMT
Company presentation scheduled on Monday, January 13th at 5:15 PM PT Ocular to provide enrollment update for SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, future opportunities for AXPAXLI, and a general corporate overview BEDFOR